GSA Capital Partners LLP Purchases New Shares in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

GSA Capital Partners LLP acquired a new position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 28,584 shares of the company's stock, valued at approximately $824,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Wolverine Asset Management LLC acquired a new stake in shares of Apellis Pharmaceuticals during the 3rd quarter valued at approximately $27,000. Capital Performance Advisors LLP acquired a new position in Apellis Pharmaceuticals during the third quarter worth $56,000. nVerses Capital LLC boosted its position in Apellis Pharmaceuticals by 300.0% during the second quarter. nVerses Capital LLC now owns 2,800 shares of the company's stock worth $107,000 after purchasing an additional 2,100 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in Apellis Pharmaceuticals by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company's stock valued at $130,000 after purchasing an additional 781 shares during the last quarter. Finally, CWM LLC increased its position in shares of Apellis Pharmaceuticals by 299.9% in the second quarter. CWM LLC now owns 4,151 shares of the company's stock valued at $159,000 after buying an additional 3,113 shares in the last quarter. 96.29% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. Oppenheimer lowered their price objective on shares of Apellis Pharmaceuticals from $65.00 to $40.00 and set an "outperform" rating on the stock in a research note on Wednesday, November 6th. Citigroup lowered their price target on shares of Apellis Pharmaceuticals from $63.00 to $51.00 and set a "buy" rating on the stock in a research report on Wednesday, November 6th. UBS Group dropped their price objective on shares of Apellis Pharmaceuticals from $85.00 to $83.00 and set a "buy" rating for the company in a research note on Friday, August 9th. Mizuho reduced their target price on Apellis Pharmaceuticals from $39.00 to $38.00 and set a "neutral" rating on the stock in a research note on Thursday, October 24th. Finally, Jefferies Financial Group reissued a "buy" rating and set a $80.00 price target on shares of Apellis Pharmaceuticals in a research report on Wednesday, July 31st. Six investment analysts have rated the stock with a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, Apellis Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus price target of $51.06.

Apellis Pharmaceuticals Trading Down 6.4 %

Shares of APLS traded down $1.79 during mid-day trading on Friday, reaching $26.27. The company had a trading volume of 5,505,260 shares, compared to its average volume of 3,342,601. Apellis Pharmaceuticals, Inc. has a fifty-two week low of $24.34 and a fifty-two week high of $73.80. The firm has a fifty day simple moving average of $29.93 and a 200-day simple moving average of $36.25. The stock has a market cap of $3.27 billion, a price-to-earnings ratio of -12.94 and a beta of 0.87. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last issued its earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.14). The firm had revenue of $196.83 million during the quarter, compared to analyst estimates of $200.00 million. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. Apellis Pharmaceuticals's revenue was up 78.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.17) EPS. On average, sell-side analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Insider Transactions at Apellis Pharmaceuticals

In related news, Director A. Sinclair Dunlop sold 37,000 shares of Apellis Pharmaceuticals stock in a transaction on Monday, September 16th. The shares were sold at an average price of $36.23, for a total transaction of $1,340,510.00. Following the transaction, the director now owns 100,000 shares in the company, valued at approximately $3,623,000. The trade was a 27.01 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 6.80% of the company's stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).